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Analysis of Chlamydia pneumoniae and AD-like Pathology in the Brains of BALB/c Mice 
Following Direct Intra-cranial Infection 
Jessica R. Barton1, Christine J. Hammond1*, Amy L. Brady, Denah M. Appelt2*, Brian J. Balin1*, and C. Scott Little1*
1Department of Pathology, Microbiology, Immunology, and Forensic Medicine, 2Department of Neuroscience, Physiology, and Pharmacology * Center for Chronic Disorders of Aging, Philadelphia College of Osteopathic Medicine, 4170 City Avenue, Philadelphia PA, 19131.
Alzheimer’s disease (AD) is an age-related progressive neurodegenerative disorder and the most common
form of dementia.  The pathology in the central nervous system (CNS) impairs memory and cognition,
hindering the capabilities and the quality of life of the individual.  This project continues studying the role
of infection and Alzheimer’s disease, as previous studies in this laboratory have done, and contributes to
the overall understanding of the possible causes of this disease.  In this study, BALB/c mice were infected,
via direct intracranial injection, with a respiratory isolate (AR-39) of Chlamydia pneumoniae.  Their
brains were analyzed at 7 and 14 days post-infection, via immunohistochemistry, for the presence of C.
pneumoniae, amyloid deposits and activated glial cells.  The goal of this project was to measure the loca-
tion and degree of C. pneumoniae burden, amyloid deposition and glial cell activation in the CNS follow-
ing direct intracranial injection and to compare this data with results obtained from previous studies in
this laboratory.  We hypothesized that C. pneumoniae antigen and activated inflammatory cells will be ob-
served in the infected mouse brains following direct intracranial injection and Aβ deposition will be ob-
served in areas where inflammation occurs.  C. pneumoniae, amyloid deposits and activated glial cells
were detected in the brains following direct intracranial infection with C. pneumoniae.  In infected mice
there was an approximate 3.5-fold increase of C. pneumoniae antigen burden compared to uninfected
mice at day 7 and there was an approximate 5.5-fold increase of C. pneumoniae antigen burden compared
to uninfected mice at day 14.  The burden of C. pneumoniae antigen, in the infected mice, increased
1.009-fold (no change) from day 7 to day 14 post-infection.  The amyloid burden in infected mice in-
creased approximately 3-fold compared to uninfected mice at day 7 and increased greater than10-fold
compared to uninfected mice at day 14. The burden of amyloid, in the infected mice, increased 7-fold
from day 7 to 14.  From 7 to 14 days post-infection the C. pneumoniae and amyloid deposits located near
the injection site spread distally from this location to other regions of the brain.  Global activation of glia
was observed in the CNS of infected mice at both 7 and 14 days post-infection. This data confirms that
C. pneumoniae is capable of establishing an infection in the CNS.  Although deposits were observed, the
lack of a substantial amount of amyloid deposits suggested that the generation of deposits may require
longer than 14 days following C. pneumoniae infection.  As early as 7 days post-infection, inflammation is
observed in response to the presence of C. pneumoniae and/or soluble amyloid in the CNS and the con-
tribution of both infection with C. pneumoniae and the presence of soluble amyloid elicit the inflamma-
tory response that presumably precedes and contributes to amyloid deposition.  
1) A C. pneumoniae antigen burden was detected in the mice at both days 7 and 14 following a dose 
of 105 infectious units of C. pneumoniae. 
• In infected mice there was an approximate 3.5-fold increase compared to uninfected mice at 
day 7. 
• In infected mice there was an approximate 5.5-fold increase compared to uninfected mice at 
day 14. 
• The burden of C. pneumoniae in infected mice increased 1.009-fold from day 7 to 14 (no 
change).
2) Following direct intracranial injection with 105 infectious units of C. pneumoniae amyloid was 
detected at all times analyzed post-infection.  
• In infected mice there was an approximate 3-fold increase compared to uninfected mice at 
day 7. 
• In infected mice there was a greater than 10-fold increase compared to uninfected mice at day
14. 
• The burden of amyloid in infected mice increased 7-fold from day 7 to 14.
3) Global activation of glia was observed in the CNS of infected mice at both 7 and 14 days post-in
fection.
I would like to express my gratitude to Gwendolyn Harley for all of the contributions she made to this
project .  She played a major role in my ability to successfully analyze several additional mice for the 
purposes of this project.  I would also like to recognize high school sophomore Guillermo Lopez for his 
assistance in the laboratory and on the microscope this summer.  In addition, I would like to thank the
Department of Pathology, Microbiology and Immunology and this institution for providing an 
opportunity to better understand the study of Alzheimer’s disease, research development and medicine at
Philadelphia College of Osteopathic Medicine (PCOM).
Chlamydia pneumoniae: Female BALB/c mice were infected with 1 x 105 infectious units, of a human
respiratory isolate of C. pneumoniae, AR-39, obtained from the American type Culture Collection
(ATCC), and propagated in HEp-2 cells, isolated for these experiments.  Infectious units were adminis-
tered via direct intracranial injection.  Hank’s balanced salt solution (HBSS) vehicle alone was given in-
tracranially for age and sex matched uninfected control mice.
Infection of Mice and Brain Removal: The injection site is located at ~Bregma -2.12mm on the
anatomical right side of the mouse brain.  At 7 or 14 days post-infection the mice were sacrificed and
perfused with 4% paraformaldehyde, immersion fixed in 4% paraformaldehyde , paraffin embedded and
then sectioned at 7-10 microns.
Mouse Brain: 50 coronal sections were labeled per mouse: 4 sets (1 per primary antibody) and 1 set (sec-
ondary antibody only) for rostral and caudal regions – 5 sections were labeled for each set. Samples rep-
resent regions spanning from rostral (bregma + 2.22mm) to caudal (bregma – 5.88mm).  
Primary Antibodies Specific for C. pneumoniae: A mouse monoclonal RDI-PROAC1p used at a
working concentration of 1:10, mouse monoclonal M6600 also used at a working concentration of 1:10,
and mouse monoclonal 10C-27 used at a working concentration of 1:100.  
Primary Antibodies Specific for Amyloid Beta 1-42 antigens: A mouse monoclonal A 1-42 (6E10)
used at a working concentration of 1:500.  
Primary Antibody Specific for Glial Fibrillary Acidic Protein (GFAP): A mouse, anti-human mono-
clonal GFAP used at a working concentration of 1:25.  
Secondary Antibodies: Alkaline phosphatase conjugated secondary antibodies were utilized to visualize
the respective antigens of interest.  All antibodies were diluted to working concentration in phosphate
buffer saline – blocking buffer.
Immunohistochemistry: The basic protocol consisted of re-hydrating sections in xylene , and then a se-
ries of graded alcohol solutions followed by DI H2O.  Slides were placed in Citra antigen retrieval buffer,
rinsed with phosphate buffer saline (PBS) pH 7.4.  Endogenous peroxidase activity was quenched utiliz-
ing a 3% solution of H2O2/PBS,then rinsed in PBS and blocked in 2% FBS/PBS.  Slides were incu-
bated in primary antibodies in a humidified chamber at 37oC. Sections were rinsed in 2% FBS/PBS,
then incubated with 2o antibodies in a 37oC humidified chamber.  Following incubation, sections were
rinsed with distilled water and developed using alkaline phosphatase new magenta, rinsed in DI H2O
and PBS followed by acidified Harris’s Hematoxylin.  Sections were rinsed thoroughly in DI H2O and
then were contrasted in PBS and rinsed with DI H O, air dried, crystal mounted and coverslipped.
Microscopic Analysis: Images were captured using NIS-Elements F 2.20 Imaging System software on a
Nikon Eclipse 50i microscope equiped with a Nikon Digital Sight DS-SM Camera.Alzheimer’s disease (AD), the most common form of dementia in elderly individuals, is an age-related,
progressive neurodegenerative disease that produces memory loss and severe cognitive impairment [1-3].
The onset of sporadic, late-onset AD (LOAD), which accounts for approximately 95% of all AD, is not
primarily due to a genetic disorder, in contrast to familial AD (FAD), and instead it increases with age,
generally occurring after age 65 [3,4].  The neuropathology shared by the two forms of AD presents as two
defining hallmarks of the disease: neurofibrillary tangles (NFTs) and neuritic (senile) plaques (NSPs).
Tangles are comprised of the abnormally hyperphosphorylated form of the tau protein whereas plaques are
extracellular accumulations of amyloid β (Aβ) peptide [3, 5-7].  
Late-onset AD seems to have multiple factors contributing to its development and ultimately leading to an
inflammatory response and the generation of Aβ resulting in neurodegeneration. LOAD is recognized as a
multifactorial disease, including the role of infectious organisms. Chronic inflammation is a hallmark of
AD, however, whether the inflammatory response results from the over expression of Aβ or other stimuli
is yet to be determined [11].  Research in this laboratory suggests that an infection with Chlamydia pneu-
moniae may be the initial stimulus for inflammation and thus the development of AD pathology [6, 9].
C. pneumoniae is an obligate intracellular bacterial pathogen that infects mucosal surfaces of the respira-
tory tract [12-14].  C. pneumoniae is generally transmitted person-to-person through aerosolized droplets
to the respiratory tract and can disseminate systemically, typically infecting and “hitching a ride” inside
monocytic cells, and has been shown to be capable of infecting an array of human cell types [9, 10, 15,
16].  Chlamydia pneumoniae infection has been associated with the onset and progression of several
chronic diseases, including AD [9, 11, 17, 18].    
This lab has developed a mouse model of AD-like pathology in which amyloid deposits have been experi-
mentally induced following infection with a human AD-isolate of the organism C. pneumoniae [4, 6].
This model is useful for exploring the early events that take place in LOAD as well as the role of infection,
particularly with the organism C. pneumoniae, in the induction of neuroinflammation and AD pathogen-
esis. Additionally, experiments utilizing a respiratory isolate of C. pneumoniae (AR-39) show that the
greatest amount of C. pneumoniae was detected at 1 month post infection (earliest time analyzed), and
then decreased at subsequent time points.  The amount of Aβ deposition peaked at 2 months post-infec-
tion, which suggests that C. pneumoniae is capable of establishing a CNS infection and promoting amy-
loid deposition.  This may serve as a stimulus for inflammation in the brain.
The work presented here aims to expand on the knowledge and data gained from our previous studies,
where mice were infected intranasally.  Following direct intracranial infection, we analyzed brain tissue for
the presence of C. pneumoniae antigen, activated glial cells and Aβ deposition in fixed and embedded
mouse brain tissue.  This project focused on determining the burden of pathogen, the mobility of the
pathogen and the presence and location of activated glial cells in the CNS. 
Figure 1. Anatomic Locations of 
Representative Coronal Sections
The numbers and corresponding lines above are 1 mm apart from one another.  The
regions boxed in red indicate the location of the injection site.  The brains were sliced
coronally starting, at line 2 above, approximately, and then separated into two halves –
rostral (BrA) and caudal (BrB).   From this initial slice (at line 2) the two halves were 
serially sectioned, every 35-50 microns and at a thickness of 7-10 microns, in both the
rostral and caudal directions – see small a rows at the top of the figure [6]. 
Figure 3.  Amyloid deposits in the brains of intracranially
infected mice
These images represent amyloid labeling observed for 
experimental mice at both 7 and 14 days post-infection.  The
top corners of each image are inset with a higher 
magnification image of amyloid deposits as designated by the
low magnification arrow.  Representative images of amyloid
deposits observed using the Aβ6E10 antibody are presented.
(Size bar = 100 µm)
Figure 5: Distribution of C. pneumoniae-specific im-
munoreactive sites, amyloid deposits and activated glial
cells at 14 days post-infection
C. pneumoniae immunoreactive sites (red dots), Aβ deposits
(blue dots) and regions of the brain with glial cell labeling
(green circles or red arrows) from individual slides in the
day 14 group are presented here in areas of the frontal 
cortex, hippocampus and dentate gyrus, as well as regions
not affected early on in Alzheimer’s disease.
Figure 6.  GFAP-specific immunoreactivity in
brain tissue of infected and control mice
Regions of the brain – hippocampus and dentate gyrus,
which are relevant structures in the AD brain – were
selected to illustrate the difference in amount of glial
cell labeling observed between a control and an 
experimental mouse at each time point.  Substantial
glial cell labeling was observed in the infected mice
and comparable sections in controls were selected for
comparison.  The red boxes in the left column of 
images represent the region of the section observed at
higher power, which are those located in the center
column.  The red boxes in the center column of 
images represent the region of the section observed at
an additionally increased power, which are those 
located in the right column.  A) This row represents
day 7 data from an uninfected, vehicle injected 
control, mouse.  B) This row represents day 7 data
from an infected mouse. C) This row represents day
14 data from an uninfected, no-injection control,
mouse. D) This row represents day 14 data from an
infected mouse.  (Size bar = 100 µm)
Figure 4. Distribution of C. pneumoniae-specific 
immunoreactive sites, amyloid deposits and activated
glial cells at 7 days post-infection
C. pneumoniae immunoreactive sites (red dots), Aβ
deposits (blue dots) and regions of the brain with glial cell
labeling (green circles or red arrows) from individual slides
in the day 7 group are presented here in areas of the 
hippocampus and dentate gyrus, as well as regions not
affected early on in Alzheimer’s disease.
Figure 2.  C. pneumoniae-specific labeling in the brains of intracranially in-
fected mice
These images represent C. pneumoniae labeling, which includes extracellular
and  intracellular, observed in the brains of experimental mice at both 7 and 14
days post-infection.  A) Representative image of extracellular labeling of C.
pneumoniae. B) Representative image of labeling of C. pneumoniae associated
with a blood vessel. C) Representative image of labeling of intracellular C.
pneumoniae. (Size bar = 100 µm)
Table 2. Total number of amyloid deposits
Table 1. Total amount of C. pneumoniae-specific labeling
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The total amount of C. pneumoniae-specific immunoreactive sites (Cpn),
intracellular, observed at both 7 and 14 days post-infection is displayed
above. 
The total number of amyloid deposits observed at both 7 and 14 days post-infection
is presented here.
